Cargando…

Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients

AIM: Ovarian cancer (OC) is one of the most lethal gynecological malignancies. Recent studies suggest a crucial role of the PD-1/PD-L1 pathway in OC pathogenesis. Therefore, our study aimed at evaluation of the clinical importance of PD-1 expression in ovarian cancer patients. PATIENTS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pawłowska, Anna, Suszczyk, Dorota, Tarkowski, Rafał, Paduch, Roman, Kotarski, Jan, Wertel, Iwona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548235/ https://www.ncbi.nlm.nih.gov/pubmed/33116828 http://dx.doi.org/10.2147/CMAR.S263010

Ejemplares similares

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2021)

Prognostic and Clinical Value of Interleukin 6 and CD45(+)CD14(+) Inflammatory Cells with PD-L1(+)/PD-L2(+) Expression in Patients with Different Manifestation of Ovarian Cancer
por: Wertel, Iwona, et al.
Publicado: (2020)

The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2022)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

Expression of Gal-9 on Dendritic Cells and Soluble Forms of TIM-3/Gal-9 in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2023)

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in the Development and/or Progression of Endometriosis-State of the Art
por: Suszczyk, Dorota, et al.
Publicado: (2021)

The Role of the Adipokine Resistin in the Pathogenesis and Progression of Epithelial Ovarian Cancer
por: Parafiniuk, Klaudia, et al.
Publicado: (2022)

Clinical Significance of Tie-2-Expressing Monocytes/Macrophages and Angiopoietins in the Progression of Ovarian Cancer—State-of-the-Art
por: Skiba, Wiktoria, et al.
Publicado: (2022)

Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy
por: Bilska, Monika, et al.
Publicado: (2020)

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
por: Pawłowska, Anna, et al.
Publicado: (2023)

Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer
por: Okła, Karolina, et al.
Publicado: (2019)

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
por: Okła, Karolina, et al.
Publicado: (2020)

Correction to: Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
por: Okła, Karolina, et al.
Publicado: (2020)

Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells
por: Surówka, J., et al.
Publicado: (2017)

γδ T Lymphocytes as a Double-Edged Sword—State of the Art in Gynecological Diseases
por: Pawłowska, Anna, et al.
Publicado: (2022)

Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy
por: Rajtak, Alicja, et al.
Publicado: (2022)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)

Quercetin and Sorafenib as a Novel and Effective Couple in Programmed Cell Death Induction in Human Gliomas
por: Jakubowicz-Gil, Joanna, et al.
Publicado: (2013)

Potentilla alba Extracts Affect the Viability and Proliferation of Non-Cancerous and Cancerous Colon Human Epithelial Cells
por: Kowalik, Klaudia, et al.
Publicado: (2020)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
por: Drakes, Maureen L., et al.
Publicado: (2018)

Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer
por: Baş, Yılmaz, et al.
Publicado: (2020)

Low-Density Lipoproteins Oxidation and Endometriosis
por: Polak, Grzegorz, et al.
Publicado: (2013)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients
por: Wertel, I., et al.
Publicado: (2015)

Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis
por: Berntsson, Jonna, et al.
Publicado: (2018)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

The Effect of Fucoidan, a Potential New, Natural, Anti-Neoplastic Agent on Uterine Sarcomas and Carcinosarcoma Cell Lines: ENITEC Collaborative Study
por: Bobiński, Marcin, et al.
Publicado: (2019)

Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
por: Zhu, Jun, et al.
Publicado: (2017)

Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma
por: Hanna, Glenn J., et al.
Publicado: (2020)

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters
por: Walankiewicz, Monika, et al.
Publicado: (2018)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer
por: Zhang, Jian, et al.
Publicado: (2019)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
por: Brinch, Charlotte Margareta, et al.
Publicado: (2022)

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2019)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”
por: Bari, Shahla, et al.
Publicado: (2019)

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hi6kodupmovogj5qqckr7jhdpb